Compare PRE & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | COYA |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.7M | 126.6M |
| IPO Year | N/A | 2022 |
| Metric | PRE | COYA |
|---|---|---|
| Price | $15.09 | $4.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $32.00 | $15.80 |
| AVG Volume (30 Days) | ★ 302.4K | 120.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,554,061.00 |
| Revenue This Year | $110.85 | $70.00 |
| Revenue Next Year | $64.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.09 | $3.94 |
| 52 Week High | $22.86 | $7.75 |
| Indicator | PRE | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 45.93 |
| Support Level | $14.83 | $4.46 |
| Resistance Level | $17.76 | $6.46 |
| Average True Range (ATR) | 1.82 | 0.24 |
| MACD | -0.58 | 0.02 |
| Stochastic Oscillator | 7.04 | 35.54 |
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.